PBI4050 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	1
299	Cystic fibrosis	1

85. Idiopathic interstitial pneumonia

Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02538536 (ClinicalTrials.gov)	July 2015	25/8/2015	A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Idiopathic Pulmonary Fibrosis (IPF)	Drug: PBI4050	Liminal BioSciences Ltd.	NULL	Completed	40 Years	N/A	All	41	Phase 2	Canada

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02955888 (ClinicalTrials.gov)	January 3, 2017	21/10/2016	Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance	A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance	Cystic Fibrosis	Drug: PBI4050;Drug: Placebo	Liminal BioSciences Ltd.	NULL	Terminated	18 Years	N/A	All	11	Phase 2	Canada